VX-809

• CAT Number: I005566
• CAS Number: 936727-05-8
• Molecular Formula: C24H18F2N2O5
• Molecular Weight: 452.41
• Purity: ≥95%
• Synonyms: VX809;VX 809
• Target: Autophagy
• Solubility: 10 mM in DMSO
• Storage: store at -20℃
• IC50: 0.1 uM (EC50)
• IUPAC Name: 3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]benzoic acid
• InChI: InChI=1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17/h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31)
• InChIKey: UFSKUSARDNFIRC-UHFFFAOYSA-N
• SMILES: OC(C1=CC(C2=C(C)C=CC(NC(C3(CC3)C4=CC(OC(F)(F)O5)=C5C=C4)=O)=N2)=CC=C1)=O

VX-809 (Lumacaftor) is a small molecule corrector of the CFTR protein, primarily studied for its role in treating cystic fibrosis (CF) caused by the F508del mutation. It works by improving the folding, trafficking, and stability of the defective CFTR protein, restoring its function on the cell surface. VX-809 is often used in combination with potentiators like ivacaftor to enhance clinical efficacy. This combination therapy has significantly advanced the management of CF, targeting the underlying cause of the disease rather than just alleviating symptoms.